The Effect of Anti-epileptic Drugs on Mitochondrial Activity
Study Details
Study Description
Brief Summary
This study is based on the hypothesis that antiepileptic drugs (other than Valproic acid) have an effect on the mitochondrial oxidative phosphorylation.
The objective of this study is to evaluate this effect in an accessible tissue-human peripheral white blood cells.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Antiepileptic drugs adverse reactions, including hepatotoxicity, are rare but potentially fatal, especially among children. Although the mechanism of the liver toxicity remains elusive, mitochondrial oxidative stress, has been hypothesized to play a role.
Most of the studies addressing antiepileptic drug effects on the mitochondria discuss the effect of valproic acid. The exact mechanisms involved in the drug-induced effects on oxidative phosphorylation are still far from being resolved. Most of the studies investigated the effect of valproic acid by using animal models or different in vitro methods.Mitochondrial diseases should be considered as a risk factor for valproic acid-induced hepatotoxicity, and there is a consensus for avoiding the administration of the drug for these patientsIs it possible that other antiepileptic drugs have similar effects? The knowledge regarding the effects of other antiepileptic drugs on the mitochondria is relatively scarce.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Antiepileptic treatment group Group of patients treated by antiepileptic medications |
Biological: antiepileptic treatment
White blood cells from peripheral blood samples
Other Names:
|
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Inclusion Criteria:
- Children between the ages of 3 and 18 years old, who suffer from new onset epilepsy as diagnosed by a certified pediatric neurologist, who do not suffer from a ''metabolic'' disorder, are treated by a single antiepileptic drug, and are not receiving any other type of medication on a chronic basis were included
Exclusion Criteria:
- Children younger than 3 years of age or older than 18 years of age, children who were suspected or known to suffer from a ''metabolic'' disorder or liver dysfunction, children who were under treatment, by any medication on a chronic basis, at the time of the study were excluded.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hadassah-Hebrew University Medical Center | Jerusalem | Israel | 91240 |
Sponsors and Collaborators
- Hadassah Medical Organization
Investigators
- Principal Investigator: Itai Berger, MD, Hadassah Medical Organization
Study Documents (Full-Text)
None provided.More Information
Publications
- 0582-09-HMO-CTIL